Abstract：
OBJECTIVE: Neuronavigation, explored as an intra-operative adjunct for brain tumor surgery three decades ago, has become globally utilized with a promising upward trajectory. This study aims to chart its success from idea to adoption and evolution within the US and globally.
METHODS: A three-pronged methodology included a systematic literature search, impact analysis using NIH relative citation ratio (RCR) and Altmetric scores, and assessment of patent holdings. Data was dichotomized for US and international contexts.
RESULTS: The first neuronavigation publication stemmed from Finland in 1993, marking its inception. Over three decades, the cumulative number of 323 studies, along with the significantly increasing publication trend (r = 0.74, p < 0.05) and distribution across 34 countries, underscored its progressive and global adoption. Neuronavigation, mostly optical systems (58%), was utilized in over 19,000 cases, predominantly for brain tumor surgery (84%). Literature impact showed a robust cumulative median RCR score surpassing that for NIH-funded studies (1.37 vs. 1.0), with US studies having a significantly higher median RCR than international (1.71 vs. 1.21, p < 0.05). Technological evolution was characterized by adjuncts, including micro/exo/endoscope (21%), MRI (17%), ultrasound (10%), and CT (7%). Patent analysis demonstrated academic and industrial representation with an interdisciplinary convergence of medical and computational sciences.
CONCLUSIONS: Since its inception thirty years ago, neuronavigation has been adopted worldwide, and it has evolved with adjunct technology integration to enhance its meaningful use. The current neuronavigation innovation pipeline is progressing, with academic and industry partnering to advance its further application in treating brain tumor patients.
METHODS: A three-pronged methodology included a systematic literature search, impact analysis using NIH relative citation ratio (RCR) and Altmetric scores, and assessment of patent holdings. Data was dichotomized for US and international contexts.
RESULTS: The first neuronavigation publication stemmed from Finland in 1993, marking its inception. Over three decades, the cumulative number of 323 studies, along with the significantly increasing publication trend (r = 0.74, p < 0.05) and distribution across 34 countries, underscored its progressive and global adoption. Neuronavigation, mostly optical systems (58%), was utilized in over 19,000 cases, predominantly for brain tumor surgery (84%). Literature impact showed a robust cumulative median RCR score surpassing that for NIH-funded studies (1.37 vs. 1.0), with US studies having a significantly higher median RCR than international (1.71 vs. 1.21, p < 0.05). Technological evolution was characterized by adjuncts, including micro/exo/endoscope (21%), MRI (17%), ultrasound (10%), and CT (7%). Patent analysis demonstrated academic and industrial representation with an interdisciplinary convergence of medical and computational sciences.
CONCLUSIONS: Since its inception thirty years ago, neuronavigation has been adopted worldwide, and it has evolved with adjunct technology integration to enhance its meaningful use. The current neuronavigation innovation pipeline is progressing, with academic and industry partnering to advance its further application in treating brain tumor patients.
摘要：
目的：神经导航，三十年前探索作为脑肿瘤手术的术中辅助手段，已经在全球范围内利用了一个有希望的上升轨迹。这项研究旨在描绘其在美国和全球范围内从想法到采用和发展的成功。
方法：三管齐下的方法包括系统的文献检索，使用NIH相对引文比率(RCR)和Altmetric评分进行影响分析，和专利持有量的评估。数据针对美国和国际背景进行了二分法。
结果：第一本神经导航出版物于1993年起源于芬兰，标志着它的诞生。三十多年来,累计323项研究，随着出版物的显着增长趋势（r=0.74，p<0.05）和分布在34个国家/地区，强调其逐步和全球采用。神经导航，主要是光学系统(58%)，在超过19,000个案例中使用，主要用于脑肿瘤手术（84%）。文献影响显示，稳健的累积中位RCR得分超过NIH资助的研究（1.37vs.1.0),美国研究的RCR中位数明显高于国际研究(1.71vs.1.21,p<0.05)。技术进化的特点是附属物，包括微型/外部/内窥镜（21％），MRI（17%），超声（10%），CT（7%）。专利分析证明了医学和计算科学的跨学科融合，具有学术和工业代表性。
结论：自30年前成立以来，神经导航已被全世界采用，并且随着辅助技术集成的发展而发展，以增强其有意义的使用。目前的神经导航创新管道正在推进，与学术和行业合作，以推进其在治疗脑肿瘤患者中的进一步应用。
方法：三管齐下的方法包括系统的文献检索，使用NIH相对引文比率(RCR)和Altmetric评分进行影响分析，和专利持有量的评估。数据针对美国和国际背景进行了二分法。
结果：第一本神经导航出版物于1993年起源于芬兰，标志着它的诞生。三十多年来,累计323项研究，随着出版物的显着增长趋势（r=0.74，p<0.05）和分布在34个国家/地区，强调其逐步和全球采用。神经导航，主要是光学系统(58%)，在超过19,000个案例中使用，主要用于脑肿瘤手术（84%）。文献影响显示，稳健的累积中位RCR得分超过NIH资助的研究（1.37vs.1.0),美国研究的RCR中位数明显高于国际研究(1.71vs.1.21,p<0.05)。技术进化的特点是附属物，包括微型/外部/内窥镜（21％），MRI（17%），超声（10%），CT（7%）。专利分析证明了医学和计算科学的跨学科融合，具有学术和工业代表性。
结论：自30年前成立以来，神经导航已被全世界采用，并且随着辅助技术集成的发展而发展，以增强其有意义的使用。目前的神经导航创新管道正在推进，与学术和行业合作，以推进其在治疗脑肿瘤患者中的进一步应用。
